Page last updated: 2024-10-25

cilostazol and Coronary Restenosis

cilostazol has been researched along with Coronary Restenosis in 55 studies

Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.

Research Excerpts

ExcerptRelevanceReference
"We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)."9.13Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
"Cilostazol has been reported to control neointimal proliferation after stenting."5.31Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT). ( Awata, N; Kobayashi, T; Otsuji, S; Sakurai, M; Takeda, Y; Tsuchikane, E, 2002)
"We sought to evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES) implantation in patients with diabetes mellitus (DM)."5.13Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
" In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis."4.88Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012)
"Cilostazol was associated with a significant reduction in late loss in BMS (mean difference 0."3.84Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. ( Chen, KY; Chetcuti, S; Grossman, MP; Gurm, H; Meier, P; Rha, SW; Tamhane, U, 2009)
" Meta-analyses evaluated effectiveness and adverse side effects for one-month administrations of aspirin plus cilostazol or aspirin plus ticlopidine therapy after coronary stenting."3.81Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. ( Hashiguchi, M; Kishino, S; Mochizuki, M; Nakazawa, R; Ohno, K; Shiga, T, 2004)
" Long-term administration of cilostazol is more effective in reducing neointimal formation at non-overlapping segments of BESs in a porcine coronary model."3.79The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model. ( Ahn, Y; Cho, JG; Hong, YJ; Jeong, MH; Kang, JC; Kim, JH; Kim, JM; Kim, KH; Lee, KH; Lim, KS; Park, DS; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS, 2013)
"Treatment with cilostazol is likely a cost-saving or dominant strategy in patients with successful coronary bare metal stent implantation."2.72Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial. ( Anderson, GT; Douglas, JS; Foster, JK; Jurkovitz, CT; Kolm, P; Murrah, NV; Parker, KM; Weintraub, WS; Zhang, Z, 2006)
"Cilostazol has properties that may reduce or avert in-stent coronary restenosis."2.71Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial. ( Douglas, JS; Holmes, D; Weintraub, WS, 2003)
"Cilostazol has been used for antiplatelet therapy after coronary stent implantation, but the results are controversial."2.71RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome. ( Chen, J; Du, Z; Ge, J; Han, Y; Jiang, H; Sun, B; Zhang, S, 2005)
"Cilostazol is a newly developed antiplatelet drug that has been widely applied for clinical use."2.70Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. ( Inoue, T; Kamishirado, H; Mizoguchi, K; Morooka, S; Nakata, T; Sakuma, M; Takayanagi, K; Uchida, T, 2002)
"In this meta-analysis, TAT was associated with significantly effective outcomes for TLR and TVR without any increase in major adverse events but was associated with tolerance issues compared with DAT after DES implantation."2.49Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. ( Bonneau, HN; Kaneda, H; Koo, BK; Nagai, R; Sakurai, R, 2013)
"Cilostazol is a generic drug with antiplatelet and antiproliferative effects."2.48Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. ( Eisenberg, MJ; Friedland, SN; Shimony, A, 2012)
" There is also no significant difference in major adverse cardiac and cerebrovascular events between the 2 therapies, except the smaller occurrence rate of target-lesion revascularization in the triple-therapy group (OR: 0."2.48The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis. ( He, J; He, Y; Liu, G; Ma, C; Tang, P; Wang, P; Yang, J; Zhou, R; Zhou, S, 2012)
"Cilostazol is a phosphodiesterase inhibitor licensed for treating patients suffering from intermittent claudication."2.45A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. ( Dindyal, S; Kyriakides, C, 2009)
"Cilostazol is a phosphodiesterase III inhibitor with pharmacological effects that include vasodilation, inhibition of platelet activation and aggregation, inhibition of thrombosis, increased blood flow to the limbs, improvement in serum lipids with lowering of triglycerides and elevation of high density lipoprotein cholesterol, and inhibition of vascular smooth muscle cell growth."2.43The vascular effects of cilostazol. ( Weintraub, WS, 2006)
"Cilostazol is a vasodilating antiplatelet agent that reversibly inhibits platelet aggregation induced by many factors."2.41Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting. ( El-Beyrouty, C; Spinler, SA, 2001)
"Cilostazol has also been reported to inhibit smooth muscle cell proliferation in vitro and has been demonstrated in a clinical study to favorably alter plasma lipids: to decrease triglyceride and to increase HDL-cholesterol levels."2.41Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. ( Kambayashi Ji, J; Liu, Y; Shakur, Y; Yoshitake, M, 2001)
" The main outcomes of the study included major adverse cardiac events (MACEs) and bleeding events during 12 months of follow-up."1.48The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis. ( Cheng, JH; Feng, ZW; Hu, ZH; Li, XY; Lv, QZ; Shi, HT; Wang, QB; Wang, Z; Wu, HY; Xie, XQ; Xu, Q; Xue, Y, 2018)
"6 months, major adverse cardiac and cerebrovascular events (MACCE) occurred in 43 patients (17."1.39Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease. ( Choi, RK; Hwang, HK; Lee, HJ; Li, H; Park, JS; Ro, YM; Yu, CW, 2013)
" At 7 and 30 days, the composite outcome for the group treated with cilostazol alone and that treated with abciximab in combination with cilostazol did not differ significantly."1.34Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting. ( Hong, EH; Kim, MY; Lee, MH; Oh, JM; Park, JE; Shin, WG, 2007)
"Cilostazol has been reported to control neointimal proliferation after stenting."1.31Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT). ( Awata, N; Kobayashi, T; Otsuji, S; Sakurai, M; Takeda, Y; Tsuchikane, E, 2002)

Research

Studies (55)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's30 (54.55)29.6817
2010's25 (45.45)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Xue, Y1
Feng, ZW1
Li, XY1
Hu, ZH1
Xu, Q1
Wang, Z1
Cheng, JH1
Shi, HT1
Wang, QB1
Wu, HY1
Xie, XQ1
Lv, QZ1
Suh, JW1
Lee, SP1
Park, K1
Kang, HJ1
Koo, BK2
Cho, YS1
Youn, TJ1
Chae, IH2
Choi, DJ1
Rha, SW2
Bae, JH2
Kwon, TG1
Bae, JW1
Cho, MC1
Kim, HS4
Lee, SW11
Ahn, JM2
Han, S2
Park, GM2
Cho, YR2
Lee, WS2
Jang, JY2
Kwon, CH2
Lee, JY4
Kim, WJ4
Kang, SJ4
Kim, YH8
Lee, CW8
Kim, JJ5
Park, SW8
Park, SJ8
Lee, HJ1
Yu, CW2
Hwang, HK1
Choi, RK1
Park, JS1
Li, H1
Ro, YM1
Park, DW5
Park, YK1
Youn, YJ1
Lee, JW1
Ahn, SG1
Lee, SH1
Choi, H1
Hong, YJ2
Kwon, HM1
Hong, MK6
Jang, Y1
Yoon, J1
Guerra, E1
Byrne, RA1
Kastrati, A2
Inoue, T3
de Donato, G1
Setacci, F1
Mele, M1
Giannace, G1
Galzerano, G1
Setacci, C1
Zuliani Mauro, MF1
Mangione, JA1
Costa, JR1
Costa, R1
Piva E Mattos, LA1
Staico, R1
Feres, F1
Siqueira, D1
Sousa, A1
Abizaid, A1
Biondi-Zoccai, GG1
Lotrionte, M1
Anselmino, M1
Moretti, C1
Agostoni, P1
Testa, L1
Abbate, A1
Cosgrave, J1
Laudito, A1
Trevi, GP1
Sheiban, I1
Dindyal, S1
Kyriakides, C1
Amasyali, B1
Celik, T1
Iyisoy, A1
Kilic, A1
Isik, E1
Tamhane, U1
Meier, P1
Chetcuti, S1
Chen, KY1
Grossman, MP1
Gurm, H1
Jennings, DL1
Kalus, JS1
Chun, KJ2
Yun, SC3
Rhee, KS1
Chae, JK1
Ko, JK2
Park, JH3
Lee, JH3
Choi, SW3
Jeong, JO1
Seong, IW3
Jon, S1
Cho, YH3
Lee, NH3
Kim, JH5
Shin, WY1
Lee, SJ1
Hyon, MS1
Bang, DW1
Choi, YJ1
Lee, BK2
Lee, K1
Park, HK1
Park, CB1
Lee, SG1
Kim, MK1
Park, KH2
Park, WJ1
Dihu, JB1
Abudayyeh, I1
Saudye, HA1
Gurujal, R1
Pant, S1
Neupane, P1
Ramesh, KC1
Barakoti, M1
Porto, I1
D'Amario, D1
Crea, F1
Friedland, SN1
Eisenberg, MJ1
Shimony, A1
Hirayama, H1
Wang, P1
Zhou, S1
Zhou, R1
Liu, G1
Tang, P1
He, J1
Ma, C1
He, Y1
Yang, J1
Jeong, YH2
Park, Y1
Muse, WC1
Kwon, TJ1
Koh, JS1
Hwang, SJ1
Kwak, CH1
Hwang, JY1
Sakurai, R1
Kaneda, H1
Bonneau, HN1
Nagai, R1
Jang, JS1
Jin, HY1
Seo, JS1
Yang, TH1
Kim, DK2
Kim, DS1
Seol, SH1
Kim, DI1
Cho, KI1
Kim, BH1
Park, YH1
Je, HG1
Geng, DF1
Liu, M1
Jin, DM1
Wu, W1
Deng, J2
Wang, JF1
Jeong, MH2
Kim, JM1
Park, DS1
Lim, KS1
Lee, KH1
Sim, DS1
Yoon, HJ1
Yoon, NS1
Kim, KH2
Park, HW1
Ahn, Y2
Cho, JG1
Park, JC1
Kang, JC1
Kamishirado, H1
Mizoguchi, K1
Uchida, T2
Nakata, T1
Sakuma, M2
Takayanagi, K1
Morooka, S1
Silber, S1
Tsuchikane, E1
Kobayashi, T2
Takeda, Y1
Otsuji, S1
Sakurai, M1
Awata, N1
Douglas, JS6
Weintraub, WS5
Holmes, D1
Mintz, GS1
Song, JM1
Han, KH2
Kang, DH1
Song, JK1
Foster, J2
Culler, SD1
Becker, ER1
Parker, K2
Zhang, Z2
Kolm, P2
Sekiguchi, M1
Hoshizaki, H1
Adachi, H1
Ohshima, S1
Taniguchi, K1
Kurabayashi, M1
Hashiguchi, M1
Ohno, K1
Nakazawa, R1
Kishino, S1
Mochizuki, M1
Shiga, T1
Imoto, Y1
Ozeki, Y1
Ozaki, Y1
Hikichi, Y1
Node, K1
Conti, CR1
Ge, J2
Han, Y2
Jiang, H1
Sun, B1
Chen, J1
Zhang, S1
Du, Z1
Wang, S1
Li, Y1
Jing, Q1
Ma, Y1
Yang, G1
Yu, H1
Holmes, DR1
Kereiakes, DJ1
Grines, CL1
Block, E1
Ghazzal, ZM1
Morris, DC1
Liberman, H1
Jurkovitz, C1
Murrah, N1
Hyde, P1
Mancini, GB1
Schömig, A1
Wessely, R1
Morishita, R1
Ujiie, Y1
Hirosaka, A1
Mitsugi, M1
Ohwada, T1
Igarashi, M1
Kijima, M1
Komatsu, N1
Hisa, S1
Abe, Y1
Tsuda, T1
Yaoita, H1
Maehara, K1
Maruyama, Y1
Foster, JK1
Jurkovitz, CT1
Parker, KM1
Murrah, NV1
Anderson, GT1
Hong, EH1
Kim, MY1
Park, JE1
Lee, MH1
Oh, JM1
Shin, WG1
Jang, S1
Chi, HS1
Jeong, JW1
Ahn, TH1
Kang, WC1
Park, CG1
Nam, CW1
Hur, SH1
Kim, KY1
Oh, SK1
El-Beyrouty, C1
Spinler, SA1
Liu, Y1
Shakur, Y1
Yoshitake, M1
Kambayashi Ji, J1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Trial of Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients With Long or Multi-vessel Coronary Artery Disease Underwent Biolimus-Eluting Stent Implantation[NCT01192724]Phase 4630 participants (Actual)Interventional2010-03-31Completed
Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214]Phase 4826 participants (Actual)Interventional2016-11-30Completed
Comparison of Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Implantation For Long Coronary Lesions[NCT00589927]Phase 4486 participants (Anticipated)Interventional2007-12-31Completed
Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.[NCT02219802]120 participants (Anticipated)Interventional2014-08-31Not yet recruiting
Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733]Phase 480 participants (Actual)Interventional2009-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

20 reviews available for cilostazol and Coronary Restenosis

ArticleYear
Pharmacological inhibition of coronary restenosis: systemic and local approaches.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:15

    Topics: Anti-Bacterial Agents; Antioxidants; Cilostazol; Coronary Restenosis; Drug Delivery Systems; Drug-El

2014
Restenosis after Coronary and Peripheral Intervention: Efficacy and Clinical Impact of Cilostazol.
    Annals of vascular surgery, 2017, Volume: 41

    Topics: Cardiovascular Agents; Cilostazol; Coronary Artery Disease; Coronary Restenosis; Endovascular Proced

2017
Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention.
    American heart journal, 2008, Volume: 155, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coronary Restenosis; Humans; Platelet Aggregation Inhibi

2008
A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy.
    Recent patents on cardiovascular drug discovery, 2009, Volume: 4, Issue:1

    Topics: Angioplasty; Arterial Occlusive Diseases; Cilostazol; Clinical Trials as Topic; Coronary Restenosis;

2009
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2009, Volume: 5, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis

2009
Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:4

    Topics: Aspirin; Cilostazol; Coronary Restenosis; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting

2010
Cilostazol and primary-PCI: mirage or good alternative?
    Current vascular pharmacology, 2012, Volume: 10, Issue:4

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol;

2012
Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention.
    The American journal of cardiology, 2012, May-15, Volume: 109, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coronary Restenosis; Global Health; Humans; Incidence; M

2012
The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.
    Clinical cardiology, 2012, Volume: 35, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Confidence Intervals; Coronary Art

2012
Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials.
    International journal of cardiology, 2013, Sep-01, Volume: 167, Issue:5

    Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Therapy, Combin

2013
A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
    Cardiology, 2012, Volume: 122, Issue:3

    Topics: Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Com

2012
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
    Cardiology, 2012, Volume: 122, Issue:3

    Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil

2012
[Antiproliferative coated stents and intracoronary brachytherapy: common traits and differences].
    Zeitschrift fur Kardiologie, 2002, Volume: 91, Issue:6

    Topics: Brachytherapy; Cell Division; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coated Materials, B

2002
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
    Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:3

    Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels;

2004
Role of adjunct pharmacologic therapy in the era of drug-eluting stents.
    Atherosclerosis. Supplements, 2005, Dec-15, Volume: 6, Issue:4

    Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Restenosis; Hu

2005
A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis.
    Atherosclerosis. Supplements, 2005, Dec-15, Volume: 6, Issue:4

    Topics: Cilostazol; Coronary Restenosis; Humans; Muscle, Smooth, Vascular; Platelet Aggregation Inhibitors;

2005
The vascular effects of cilostazol.
    The Canadian journal of cardiology, 2006, Volume: 22 Suppl B

    Topics: Animals; Cell Proliferation; Cilostazol; Coronary Restenosis; Endothelium, Vascular; Humans; Lipids;

2006
Pharmacologic approaches to restenosis prevention.
    The American journal of cardiology, 2007, Sep-03, Volume: 100, Issue:5A

    Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease

2007
Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting.
    The Annals of pharmacotherapy, 2001, Volume: 35, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cilostazol; Coronary Disease; Coronary Restenosis;

2001
Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
    Cardiovascular drug reviews, 2001,Winter, Volume: 19, Issue:4

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adenosine; Angioplasty, Balloon, Coronary; Animals; Arterial Oc

2001

Trials

23 trials available for cilostazol and Coronary Restenosis

ArticleYear
The Effect of Cilostazol on the Angiographic Outcome of Drug-Eluting Coronary Stents Angiographic Analysis of the CILON-T (Influence of CILostazol-Based Triple Antiplatelet Therapy ON Ischemi Complication after Drug-Eluting StenT Implantation) Trial.
    International heart journal, 2017, Dec-12, Volume: 58, Issue:6

    Topics: Aged; Antineoplastic Agents; Cilostazol; Coronary Angiography; Coronary Restenosis; Drug Therapy, Co

2017
Differential impact of cilostazol on restenosis according to implanted stent type (from a pooled analysis of three DECLARE randomized trials).
    The American journal of cardiology, 2013, Nov-01, Volume: 112, Issue:9

    Topics: Cilostazol; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Dose-Response Relati

2013
Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials).
    The American journal of cardiology, 2013, Dec-01, Volume: 112, Issue:11

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Diabetes Compl

2013
Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease.
    American heart journal, 2014, Volume: 167, Issue:2

    Topics: Aged; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; D

2014
Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
    The Journal of invasive cardiology, 2017, Volume: 29, Issue:3

    Topics: Aspirin; Cilostazol; Clopidogrel; Comorbidity; Coronary Angiography; Coronary Artery Disease; Corona

2017
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2009, Volume: 5, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis

2009
Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
    The American journal of cardiology, 2010, Jan-15, Volume: 105, Issue:2

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Diabete

2010
A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Sten
    Journal of the American College of Cardiology, 2011, Mar-15, Volume: 57, Issue:11

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Double-Blind M

2011
Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.
    American heart journal, 2002, Volume: 144, Issue:2

    Topics: Aged; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Coronary Restenosis; Drug Therapy

2002
Rationale and design of the randomized, multicenter, cilostazol for RESTenosis (CREST) trial.
    Clinical cardiology, 2003, Volume: 26, Issue:10

    Topics: Adolescent; Aspirin; Cilostazol; Coronary Angiography; Coronary Restenosis; Double-Blind Method; Fem

2003
Methods for the economic and quality of life supplement to the cilostazol for RESTenosis (CREST) trial.
    The Journal of invasive cardiology, 2004, Volume: 16, Issue:5

    Topics: Angioplasty, Balloon, Coronary; Chemoprevention; Cilostazol; Coronary Restenosis; Cost-Benefit Analy

2004
Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol.
    Circulation journal : official journal of the Japanese Circulation Society, 2004, Volume: 68, Issue:7

    Topics: Aged; Cilostazol; Coronary Restenosis; Coronary Stenosis; Equipment Design; Female; Follow-Up Studie

2004
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting.
    Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:3

    Topics: Administration, Oral; Aspirin; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Vessels;

2004
Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.
    Journal of the American College of Cardiology, 2004, Oct-06, Volume: 44, Issue:7

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Cilostazol; Coronary Angiography; Coronary Artery Disease

2004
Comparison of cilostazol and clopidogrel after successful coronary stenting.
    The American journal of cardiology, 2005, Apr-01, Volume: 95, Issue:7

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Female;

2005
RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome.
    Journal of cardiovascular pharmacology, 2005, Volume: 46, Issue:2

    Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; China; Cilostazol; Coronary Angiography; Co

2005
Cilostazol improves long-term outcomes after coronary stent implantation.
    American heart journal, 2005, Volume: 150, Issue:3

    Topics: Cilostazol; Coronary Restenosis; Coronary Stenosis; Humans; Platelet Aggregation Inhibitors; Prospec

2005
Coronary stent restenosis in patients treated with cilostazol.
    Circulation, 2005, Nov-01, Volume: 112, Issue:18

    Topics: Aged; Angina, Unstable; Aspirin; Cilostazol; Coronary Restenosis; Double-Blind Method; Female; Human

2005
Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis.
    International heart journal, 2006, Volume: 47, Issue:2

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists;

2006
Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial.
    American heart journal, 2006, Volume: 152, Issue:4

    Topics: Adult; Cilostazol; Coronary Restenosis; Coronary Stenosis; Cost-Benefit Analysis; Double-Blind Metho

2006
Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation.
    The American journal of cardiology, 2007, Aug-15, Volume: 100, Issue:4

    Topics: Aspirin; Biomarkers; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Coronary Resteno

2007
Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients--clilostazol for diabetic patients in drug-eluting stent (CIDES) trial.
    Circulation journal : official journal of the Japanese Circulation Society, 2008, Volume: 72, Issue:1

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest

2008
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im
    Journal of the American College of Cardiology, 2008, Mar-25, Volume: 51, Issue:12

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest

2008

Other Studies

14 other studies available for cilostazol and Coronary Restenosis

ArticleYear
The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation: a combined clinical study and computational system pharmacology analysis.
    Acta pharmacologica Sinica, 2018, Volume: 39, Issue:2

    Topics: Aged; Asian People; Aspirin; China; Cilostazol; Clopidogrel; Coronary Restenosis; Data Interpretatio

2018
Long-term effectiveness and safety of triple versus dual antiplatelet therapy after percutaneous coronary intervention for unprotected left main coronary artery disease.
    Coronary artery disease, 2013, Volume: 24, Issue:7

    Topics: Aged; Cerebrovascular Disorders; Cilostazol; Coronary Restenosis; Coronary Stenosis; Coronary Thromb

2013
[Cilostazol].
    Nihon rinsho. Japanese journal of clinical medicine, 2016, Jun-20, Volume: 74 Suppl 4 Pt 1

    Topics: Cilostazol; Coronary Restenosis; Humans; Percutaneous Coronary Intervention; Phosphodiesterase 3 Inh

2016
Oral triple antiplatelet therapy after percutaneous coronary intervention: subject with ongoing arguments?
    International journal of cardiology, 2010, Sep-24, Volume: 144, Issue:1

    Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Res

2010
Cilostazol: a potential therapeutic option to prevent in-stent restenosis.
    Journal of the American College of Cardiology, 2011, May-17, Volume: 57, Issue:20

    Topics: Cilostazol; Coronary Restenosis; Drug-Eluting Stents; Humans; Prosthesis Failure; Tetrazoles

2011
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity.
    Cardiology journal, 2011, Volume: 18, Issue:6

    Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistan

2011
[Cilostazol].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 7

    Topics: Animals; Cilostazol; Coronary Restenosis; Humans; Platelet Aggregation Inhibitors; Stents; Tetrazole

2011
Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study.
    Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:8

    Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Cilostazol; Cl

2012
The impact of triple anti-platelet therapy for endothelialization and inflammatory response at overlapping bioabsorbable polymer coated drug-eluting stents in a porcine coronary model.
    International journal of cardiology, 2013, Oct-03, Volume: 168, Issue:3

    Topics: Absorbable Implants; Animals; Aspirin; Cilostazol; Clopidogrel; Coated Materials, Biocompatible; Cor

2013
Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT).
    The American journal of cardiology, 2002, Sep-15, Volume: 90, Issue:6

    Topics: Aged; Atherectomy, Coronary; Blood Vessel Prosthesis Implantation; Cilostazol; Combined Modality The

2002
Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation.
    Circulation, 2004, Feb-24, Volume: 109, Issue:7

    Topics: Aged; Aspirin; Atherectomy, Coronary; Catheterization; Cilostazol; Combined Modality Therapy; Corona

2004
Not just another restenosis trial.
    Clinical cardiology, 2004, Volume: 27, Issue:10

    Topics: Angioplasty, Balloon, Coronary; Cilostazol; Combined Modality Therapy; Coronary Artery Disease; Coro

2004
Prevention of restenosis by systemic drug therapy: back to the future?
    Circulation, 2005, Nov-01, Volume: 112, Issue:18

    Topics: Cilostazol; Controlled Clinical Trials as Topic; Coronary Restenosis; Double-Blind Method; Drug Admi

2005
Efficacy and safety of abciximab in combination with cilostazol in patients undergoing stenting.
    International journal of clinical pharmacology and therapeutics, 2007, Volume: 45, Issue:6

    Topics: Abciximab; Aged; Angina, Unstable; Antibodies, Monoclonal; Cilostazol; Coronary Angiography; Coronar

2007